Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial
- jeanfrancoismaison
- May 12
- 1 min read
top of page
Search
Recent Posts
See Allhttps://pubmed.ncbi.nlm.nih.gov/40467521/
https://pubmed.ncbi.nlm.nih.gov/40450523/
https://pubmed.ncbi.nlm.nih.gov/40464483/
bottom of page
Comments